ALXP
ALCOX
Market cap132mUSD
Oct 21, Last price
3.34EUR
Name
Nicox
Chart & performance
P/E
—
P/S
9.99
EPS
—
Div yield, %
—
Shrs. gr., 5y
19.23%
Rev. gr., 5y
3.05%
Revenues
17m
+113.32%
Net income
0
P
CFO
0
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nicox S.A. is an international ophthalmic pharmaceutical company, headquartered in Valbonne, France, and established in 1996. Its core mission is to develop innovative treatments aimed at preserving sight and enhancing overall eye health. The company's primary investigational compound, NCX 470, a cutting-edge nitric oxide-donating prostaglandin analog, is currently undergoing Phase 3 clinical trials. This candidate is designed to reduce elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Additionally, Nicox is advancing NCX 4251, a unique fluticasone formulation in Phase 2b clinical trials, specifically targeting severe flare-ups of blepharitis, alongside another promising candidate, NCX 1728, also under development. Beyond its pipeline, Nicox markets two key ophthalmic solutions: VYZULTA (latanoprostene bunod), prescribed for the management of open-angle glaucoma or ocular hypertension, and ZERVIATE (cetirizine), used to alleviate eye itching caused by allergic conjunctivitis.
Key people
Sandrine Gestin
Finance Director, Member of the Management Committee · since 2015
Gavin Spencer
Executive Vice President & Chief Business Officer, Member of the Management Committee · since 2017
Michael Bergamini
Executive Vice President, Chief Scientific Officer, Member of the Management Committee · since 2015
Vice President, Head of Development, Member of the Management Committee · since 2018
Emmanuelle Pierry
Senior Director of Legal Affairs, Member of the Management Committee
Non-Executive Independent Director · since 2014
Lester J. Kaplan
Non-Executive Independent Director · since 2014
Non-Executive Independent Director · since 2017
Headquarters & legal address
SOPHIA
EMERALD SQUARE
BIOT 06410
FR
EMERALD SQUARE
BIOT 06410
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||